SGLT‐1 has been implicated in cancer cell survival via glucose uptake; therefore, canagliflozin's inhibition of both SGLT‐1 and SGLT‐2 receptors has been proposed for this agent's purported protective effect.18 Here, SLC5A1 is linked to cancer.